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Abstract
Practice guidelines incorporate genomic tumor profiling, using results such as the Oncotype DX 
Recurrence Score (RS), to refine recurrence risk estimates for the large proportion of breast cancer 
patients with early-stage, estrogen receptor-positive disease. We sought to understand the impact 
of receiving genomic recurrence risk estimates on breast cancer patients’ well-being and the 
impact of these patient-reported outcomes on receipt of adjuvant chemotherapy. Participants were 
193 women (mean age 57) newly diagnosed with early-stage breast cancer. Women were 
interviewed before and 2–3 weeks after receiving the RS result between 2011 and 2015. We 
assessed subsequent receipt of chemotherapy from chart review. After receiving their RS, 
perceived pros (t = 4.27, P < .001) and cons (t = 8.54, P <.001) of chemotherapy increased from 
pre-test to post-test, while perceived risk of breast cancer recurrence decreased (t = 2.90, P = .
004). Women with high RS tumors were more likely to receive chemotherapy than women with 
low RS tumors (88 vs. 5 %, OR 0.01, 0.00–0.02, P < .001). Higher distress (OR 2.19, 95 % CI 
1.05–4.57, P < .05) and lower perceived cons of chemotherapy (OR 0.50, 95 % CI 0.26–0.97, P < .
05) also predicted receipt of chemotherapy. Distressed patients who saw few downsides of 
chemotherapy received this treatment. Clinicians should consider these factors when discussing 
chemotherapy with breast cancer patients.
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Introduction
Several clinical practice guidelines incorporate genomic profiling of early-stage, estrogen 
receptor-positive (ER+) breast tumors with specific pathologic features (i.e., node-negative) 
to refine recurrence estimates and guide decisions about adjuvant chemotherapy [1–4]. 
Multiple recent studies demonstrate continued adoption of genomic testing in breast cancer 
treatment decision making [5–7]. As research continues on the clinical utility of genomic 
tests, significant challenges arise in effectively communicating this risk information to 
patients and integrating this information with patient preferences to inform treatment 
decisions.
The Oncotype DX Breast Cancer Assay, a widely used genomic test, is a 21-gene assay that 
measures breast cancer recurrence risk and chemotherapy benefit in early-stage, estrogen 
receptor-positive patients. The results are expressed as a Recurrence Score (RS) that is 
categorized as low, intermediate, or high. These results, when combined with standard 
pathological tumor features, provide information that oncologists and patients can use in 
making chemotherapy treatment decisions. For example, patients with high RS tumors have 
been shown to derive benefit from adding chemotherapy to prescribed hormonal therapy in 
order to decrease their risk of recurrence, whereas patients with a low RS can be treated with 
hormonal therapy alone, safely avoiding chemotherapy and its side effects [8–10]. Several 
clinical studies have demonstrated that the RS informs oncologists’ and patients’ treatment 
decisions [5, 11–13]. In one recent study, oncologists changed their recommendation from 
chemotherapy plus hormone therapy to hormone therapy alone in 25–44 % of patients who 
received their RS [14]. Patients and oncologists endorse the value of testing in treatment 
decision making, especially when there is uncertainty regarding treatment plans in the 
context of existing pathology alone [15–17].
Testing occurs in the broader context of breast cancer treatment decisions that are already 
complex and stressful [18]. Many women with early-stage breast cancer are reluctant to 
decline chemotherapy due to concerns about the possibility of recurrence and a desire to do 
everything possible to fight their cancer [19–21]. These decisions can be driven by perceived 
risk of recurrence, distress related to the diagnosis, and the advantages and drawbacks 
women perceive regarding chemotherapy treatment (i.e., perceived pros and cons) [19, 22, 
23]. We do not yet know whether receipt of their RS leads to a shift in these variables, or 
how these factors and the RS contribute to whether patients receive chemotherapy above and 
beyond the contribution of demographic and clinical variables.
In the present study, we sought to assess whether receipt of the RS changed patient-reported 
outcomes and whether these factors predicted chemotherapy. We hypothesized that patients 
with low RS would report decreases in perceived risk, distress and perceived pros of 
chemotherapy and increases in cons of chemotherapy, and those with high RS would report 
increased perceived risk, distress and perceived pros with decreased cons. We also examined 
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whether perceived risk of recurrence, cancer-related distress, and the perceived pros and 
cons of chemotherapy were prospectively associated with receipt of chemotherapy. We 
hypothesized that women with a high RS tumor would be more likely to receive 
chemotherapy than those with intermediate or low RS tumors, and that women with greater 
perceived risk of recurrence, distress, stronger perceived pros, and weaker perceived cons of 
chemotherapy would be more likely to receive this treatment.
Methods
Participants
Participants were women recruited from 2011 to 2015 through four clinical sites in 
Washington, DC (Lombardi Comprehensive Cancer Center and Washington Hospital 
Center), Maryland (Franklin Square Medical Center), and Florida (H. Lee Moffitt 
Comprehensive Cancer Center). Eligible participants were recently diagnosed female breast 
cancer patients who had Stage I or II hormone receptor-positive tumors and received 
Oncotype DX testing. We excluded women with a prior cancer diagnosis and those who 
initiated chemotherapy or received her RS prior to the pre-test interview. We identified 
eligible women through their treating medical/surgical oncologist or from the pathology 
record tracking system of test orders. The Georgetown University Institutional Review 
Board approved our protocol. Informed consent was obtained from all individual 
participants included in the study.
Our study staff contacted eligible women for recruitment shortly after their clinicians 
ordered Oncotype DX testing. Consenting patients completed a pre-test interview via 
telephone before receiving their RS. Study staff contacted participants 2–3 weeks after the 
pre-test interview once they received their RS to schedule and complete a post-test interview. 
We identified 352 potentially eligible women diagnosed with stage I or II breast cancer for 
whom the Oncotype DX test was expected to be ordered. Sixty-four were unreachable by 
phone. Of the 288 reached, 38 were ineligible, and 19 declined participation. Two hundred 
and thirty-one women completed the pre-test interview. Seven withdrew between pre-test 
and post-test and 31 were unreachable for the post-test interview. This yielded a final sample 
of 193 participants. Study staff conducted interviews via telephone. Participants received 
$25 for each interview they completed.
Measures
Pre-test and post-test surveys
Participant characteristics: Surveys assessed age, ethnicity, education, race, marital status, 
and income (pre-test only).
Perceived recurrence risk: Surveys assessed perceived risk of recurrence using a single 
item: “What do you think the chance is that your breast cancer will come back or spread to 
other parts of the body? Please choose a number between 0 % (no chance) and 100 % 
(definitely will).”
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Cancer-specific distress: Surveys included the 15 item Impact of Event Scale (IES) [24]. 
The IES has two sub-scales which measure intrusive and avoidant ideation (possible range = 
0–60). Reliability was high for the IES at both time points (α = .88–.92).
Pros/cons of chemotherapy: Surveys measured eight pros (e.g., “To reduce the risk of my 
breast cancer coming back or spreading”) and eight cons (e.g., “I was concerned about 
severe side effects”) of chemotherapy, adapted from previously used measures [25, 26] from 
the response scale ranged from Not at all important (coded as 1) to very important (4). 
Reliability was high for pros (α = .90–.92) and cons (α = .81–.82).
Chart review—Study staff performed chart reviews to obtain RS, tumor stage, grade, 
tumor size, nodal status, hormonal therapy received, and receipt of chemotherapy.
Statistical analyses
We assessed changes between patient-reported outcomes of pre-test and post-test for 
perceived risk of recurrence, distress, and perceived pros and cons of chemotherapy. We also 
examined whether these changes differed by RS by examining the interaction with RS. We 
standardized patient-reported outcomes to support the interpretation of our results. We 
examined bivariate and multivariate correlates of chemotherapy uptake using logistic 
regression. We conducted analyses using SPSS v 23.0. Tests were 2-tailed, using a critical 
alpha of .05.
Results
Most participants were white (65 %) and had at least a college degree (60 %). Most cancers 
were Stage I (59 %) and yielded low RS (60 %) (Table 1).
Changes in patient-reported outcomes
Perceived pros of chemotherapy increased from pre-test to post-test (t = 4.27, P <.001) and 
perceived cons also increased (t = 8.54, P < .001) (Fig. 1). Perceived risk of breast cancer 
recurrence decreased over time (t = 2.90, P = .004). Cancer-related distress did not increase 
from pre-test to post-test, but the difference was marginally statistically significant (t = 1.69, 
P = .09). None of these changes differed by RS (all interactions, not statistically significant).
Receipt of chemotherapy
Overall, 24 % of patients received chemotherapy. As expected, patients with low RS tumors 
typically received hormonal therapy only (110 of 116, 95 %), while patients with high RS 
tumors typically received chemotherapy in addition to hormonal therapy (15 of 17, 88 %) 
(Table 2). Among patients with intermediate RS tumors, 57 % (34 of 60) received hormonal 
therapy only and 43 % (26 of 60) received combined therapy. In the group as a whole, on 
bivariate analyses, patients who received chemotherapy were younger than those who did 
not (OR 0.66, 95 % CI 0.47–0.94, P < .05). Higher histological grade (OR 4.06, 95 % CI 
2.16–7.66, P < .001), larger tumor size (OR 1.63, 95 % CI 1.10–2.42, P < .05), and Stage II 
versus Stage I cancers (OR 2.04, 95 % CI 1.15–3.63, P < .05) were also associated with 
greater likelihood of receiving chemotherapy.
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In multivariate analyses, younger patients (OR 0.89, 95 % CI 0.83–0.95, P < .001) were 
more likely to receive chemotherapy, as were patients with high RS tumors, as compared to 
those with intermediate (OR 0.04, 95 % CI 0.01–0.27, P < .001) or low RS tumors (OR 0.01, 
95 % CI 0.00–0.02, P < .001). Higher post-test distress (OR 2.19, 95 % CI 1.05–4.57, P < .
05) and lower perceived cons (OR 0.50, 95 % CI 0.26–0.97, P < .05) of chemotherapy 
predicted receipt of chemotherapy. The odds of receiving chemotherapy were more than two 
times higher for every half-standard deviation increase in distress and were halved for every 
half-SD increase in perceived cons. Higher perceived pros were not associated with receipt 
of this treatment, although the association was marginally statistically significant (OR 1.83, 
95 % CI 0.96–3.50, P = .07).
Discussion
Our findings suggest that breast cancer patients were responsive to their RS test results. 
Specifically, we found an increase in perceived pros and cons from pre- to post-testing; this 
finding did not differ by test result. This pattern of findings could potentially be due to a 
greater comprehension of the treatment following medical oncology appointments for 
adjuvant treatment planning in addition to the RS result itself. A recent systematic review of 
breast cancer patients’ preferences for adjuvant treatment found that while most patients 
judged that even small survival benefits would make receipt of chemotherapy worthwhile, 
preferences of individual patients varied widely across the studies included in this review. 
Further, 2–19 % of patients in the studies included in the review would refuse chemotherapy 
regardless of the survival benefits [27]. This review also found that clinical characteristics, 
such as nodal status and sociodemographics, did not predict patients’ treatment preferences. 
Evolving research suggests that patient preferences change over time. This should be 
particularly true as patients receive more information about their cancer and the potential 
benefit of chemotherapy (or the limited rationale for this treatment) and this knowledge is 
integrated with preferences within the clinical encounter [28].
Distress did not change following the receipt of the RS. Distress at pre- and post-testing in 
this sample was moderate [29]. These findings suggest that women do not experience a great 
sense of reassurance following testing. Future work could assess whether recent prospective 
validation demonstrating an excellent outcome in those with tumors with very low RS 0–10 
(5-year risk of distant relapse of 99.3 %; 95 % CI, 98.7–99.6) [30] would result in different 
patient-reported outcomes.
We also saw a decrease in perceived risk of recurrence. Few studies of tested patients have 
been designed to allow for the assessment of change in outcomes from pre- to post-testing. 
Previous studies suggest an overall decline in anxiety [31] and decisional conflict [32] 
following the receipt of the RS. Our results are similar to those of another study conducted 
within the context of the MINDACT trial, testing another common gene expression profiling 
test for breast cancer. Specifically, 6–8 weeks after surgery, women in the MINDACT trial 
who received high risk results reported higher distress and perceived risk as compared to 
those who received low risk results [33]. That we did not find increases in perceived risk of 
recurrence among high risk patients [34] perhaps was due to our much smaller sample size 
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of patients with high RS tumors. Alternatively, their perceived risk of recurrence could have 
reflected the benefit of planning to receive chemotherapy.
Our hypothesis regarding predictors of chemotherapy uptake was partially confirmed. We 
found that chemotherapy uptake was higher among women with higher cancer-related 
distress and lower perceived cons for chemotherapy, with marginal effects for perceived pros 
of chemotherapy. In contrast, perceived risk did not contribute to our model. Previous 
studies have demonstrated that higher distress can interfere with decision making [35] and 
be associated with more aggressive treatment [36]. More concerns about chemotherapy 
could elicit lower willingness on the patient’s part to follow treatment recommendations. 
This is an especially important factor considering women with high RS tumors receive 
greater benefit from chemotherapy treatment.
Our study has several strengths. To our knowledge, this is the first study to prospectively 
assess women’s distress, perceived risk of recurrence, and preferences for chemotherapy 
before and after receipt of their RS and to report differences in these variables according to 
test results. Further, our results suggest that patient-reported variables can help to explain 
treatment received following this common genomic test, above and beyond the strong effects 
for test result and patient age. Oncologists should consider the potential impact of their 
patients’ emotional state and the advantages and disadvantages they perceive from 
chemotherapy when engaging their patients in shared treatment decisions [37]. Finally, our 
sample was racially diverse and is drawn from both comprehensive cancer centers and 
community clinical settings.
In terms of limitations, while our sample was racially diverse, participants were generally 
well-educated and affluent. Our study was limited by its recruitment in clinics in the Eastern 
US, though we drew from both comprehensive cancer centers and academic community 
settings. Also, while we had a relatively low rate of active decliners, a number of patients 
were unreachable for a pre-test interview. This likely reflects our need to refine our 
recruitment approaches to reach patients in the relatively short 2-week window between 
when the test is ordered and when results are disclosed in clinic to the patient. Patients who 
were unreachable for their pre-test interview may differ from women we were able to assess 
for eligibility and consent to a pre-test interview.
Our study adds to the growing literature on outcomes among women who receive genomic 
tumor profiling when they are diagnosed with early-stage breast cancer. Our findings suggest 
potential intervention targets to improve outcomes in this population. Future research should 
examine the reason for increases in both pros and cons of treatment after testing.
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Fig. 1. 
Changes in patient-reported outcomes from pre- to post-test. Error bars report standard 
errors
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Table 1
Participant characteristics (N = 193)
N (%) M (SD)
Demographic characteristics
Age 57.14 (9.87)
Education
 ≥High school degree 33 (17.2)
 Some college 44 (22.8)
 College degree 42 (21.8)
 Graduate/professional training 74 (38.3)
Race
 White 125 (65.4)
 African American 50 (26.2)
 Asian American 10 (5.2)
 Other/missing 8 (3.4)
 Latina ethnicity 12 (6.3)
Marital status
 Married/partner 117 (62.3)
 Single/widow/divorced 76 (37.7)
Annual household income
 <$50,000 28 (14.7)
 $50,000–100,000 53 (27.5)
 >$100,000 78 (40.8)
 Missing 34 (17.6)
Breast cancer characteristics
Recurrence Score
 Low 116 (60.1)
 Intermediate 60 (30.1)
 High 17 (8.8)
Stage
 I 115 (60)
 IIA 36 (19)
 IIB 11 (6)
 Missing/undefined 31 (16)
Histologic grade
 Low 46 (23.8)
 Intermediate 81 (42.0)
 High 32 (16.6)
 Missing/undefined 34 (17.6)
Tumor size
 ≤1 cm 51 (26.4)
 1.1–2 cm 88 (45.6)
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N (%) M (SD)
 2.1–3 cm 20 (10.4)
 3.1–5 cm 13 (6.8)
 Missing/undefined 21 (10.8)
Nodal status
 Positive 16 (8.3)
 Negative 155 (80.3)
 Missing/undefined 22 (11.4)
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Table 2
Predictors of chemotherapy use
No. receiving chemotherapy/total no. (%) Bivariate OR (95 % CI) Multivariate OR (95 % CI)
Recurrence Score
 High (ref) 15/17 (88) 1.00 (ref)
 Intermediate 34/60 (57) 0.10 (0.02–0.49)** 0.04 (0.01–0.27)***
 Low 110/116 (5) 0.01 (0.00–0.04)*** 0.01 (0.00–0.02)***
Age 0.66 (0.47–0.94)* 0.89 (0.83–0.95)***
Pre-test distress 0.86 (0.61–1.19) 0.47 (0.21–1.07)+
Pre-test perceived risk 0.99 (0.98–1.01) 0.47 (.98–1.06)
Pre-test chemotherapy pros 1.15 (0.82–1.63) 1.19 (.66–2.16)
Pre-test Chemotherapy cons 0.76 (0.55–1.07) 0.74 (0.39–1.38)
Post-test distress 1.26 (0.90–1.75) 2.19 (1.05–4.57)*
Post-test perceived risk 1.01 (0.99–1.02) 1.01 (0.98–1.03)
Post-test chemotherapy pros 1.68 (1.10–2.57)* 1.83 (0.95–3.50)+
Post-test chemotherapy cons 0.61 (0.43–0.86)** 0.50 (0.26–0.97)*
In sensitivity analyses, tumor stage, size, and grade did not significantly contribute to the model and model results were similar to those presented. 
Due to this and missing data on these variables, we did not include them in the final model
+P < .10;
*P < .05;
**P < .01;
***P < .001
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